The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
 
Shinya Sakata
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma; Takeda
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Takehiro Uemura
Honoraria - AstraZeneca/Hong Kong; Boehringer Ingelheim; Chugai Pharma; Guardant Health; Lilly O.; MSD; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuko Tsuchiya-Kawano
Speakers' Bureau - AstraZeneca/Hong Kong; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Kyowa Kirin Co., Ltd.; Lilly; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
 
Mitsuo Osuga
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - Amgen; Chugai Pharma; Guardant Health; Takeda; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Takeda (Inst); Tosoh Corporation; Zeon Corporation
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - A2 Healthcare; Abbvie (Inst); Amgen; Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation; IQvia; Janssen (Inst); Lilly (Inst); Mebix; MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)